{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T10:22:19Z","timestamp":1790418139915,"version":"4.1.0"},"reference-count":77,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T00:00:00Z","timestamp":1603238400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016915","name":"Inventiva Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019328","name":"NGM Biopharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019944","name":"Sanofi-Aventis Deutschland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019944","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.cct.2020.106170","type":"journal-article","created":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T08:15:42Z","timestamp":1602144942000},"page":"106170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"special_numbering":"C","title":["A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: Design of the NATIVE study"],"prefix":"10.1016","volume":"98","author":[{"given":"Francque","family":"Sven M.","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bedossa","family":"Pierre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelmalek","family":"Manal F.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anstee","family":"Quentin M.","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bugianesi","family":"Elisabetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ratziu","family":"Vlad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huot-Marchand","family":"Philippe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scherrer","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junien","family":"Jean-Louis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Broqua","family":"Pierre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abitbol","family":"Jean-Louis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cct.2020.106170_bb0005","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1053\/j.gastro.2014.07.056","article-title":"Pathological features of fatty liver disease","volume":"147","author":"Yeh","year":"2014","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.cct.2020.106170_bb0010","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease","volume":"64","author":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO)","year":"2016","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.cct.2020.106170_bb0015","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology."},{"issue":"5","key":"10.1016\/j.cct.2020.106170_bb0020","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/hep.25889","article-title":"Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients","volume":"56","author":"Bedossa","year":"2012","journal-title":"Hepatology."},{"issue":"1","key":"10.1016\/j.cct.2020.106170_bb0025","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.cct.2020.106170_bb0030","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1053\/gast.2001.23256","article-title":"Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities","volume":"120","author":"Sanyal","year":"2001","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.cct.2020.106170_bb0035","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/hep.24001","article-title":"Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis","volume":"52","author":"Tilg","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.cct.2020.106170_bb0040","series-title":"Non-Alcoholic Steatohepatitis: The Role of Peroxisome Proliferator-Activated Receptors to be published","author":"Francque","year":"2020"},{"issue":"5","key":"10.1016\/j.cct.2020.106170_bb0045","first-page":"809","article-title":"Roles of PPARs in NAFLD: potential therapeutic targets","volume":"1281","author":"Tailleux","year":"2012","journal-title":"Biochem. Biophys. Acta"},{"issue":"4","key":"10.1016\/j.cct.2020.106170_bb0050","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1124\/pr.58.4.5","article-title":"International Union of pharmacology. LXI. Peroxisome proliferator-activated receptors","volume":"58","author":"Michalik","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.cct.2020.106170_bb0055","first-page":"13675","article-title":"The role and regulation of the peroxisome proliferator activated receptor alpha in human liver","author":"Kersten","year":"2017","journal-title":"Biochimie"},{"issue":"2","key":"10.1016\/j.cct.2020.106170_bb0060","doi-asserted-by":"crossref","first-page":"332","DOI":"10.2337\/db07-1318","article-title":"Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men","volume":"57","author":"Ris\u00e9rus","year":"2008","journal-title":"Diabetes"},{"key":"10.1016\/j.cct.2020.106170_bb0065","first-page":"501087","article-title":"Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis","author":"Gastaldelli","year":"2009","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cct.2020.106170_bb0070","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"issue":"20","key":"10.1016\/j.cct.2020.106170_bb0075","article-title":"Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"S0016-5085","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.cct.2020.106170_bb0080","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1210\/jc.2009-1487","article-title":"Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome","volume":"95","author":"Belfort","year":"2010","journal-title":"J. Clin. Endocrinol. Metabol."},{"issue":"3","key":"10.1016\/j.cct.2020.106170_bb0085","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1172\/JCI27989","article-title":"Sorting out the roles of PPAR alpha in energy metabolism and vascular homeostasis","volume":"116","author":"Lefebvre","year":"2006","journal-title":"J. Clin. Invest."},{"issue":"6","key":"10.1016\/j.cct.2020.106170_bb0090","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.cmet.2008.04.003","article-title":"Alternative M2 activation of Kupffer cells by PPAR\u03b4 ameliorates obesity-induced insulin resistance","volume":"7","author":"Odegaard","year":"2008","journal-title":"Cell Metab."},{"issue":"6","key":"10.1016\/j.cct.2020.106170_bb0095","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.biocel.2010.02.006","article-title":"Peroxisome proliferator-activated receptors gamma reverses hepatic nutritional fibrosis in mice and suppresses activation of hepatic stellate cells in vitro","volume":"42","author":"Yu","year":"2010","journal-title":"Intern. J. Biochem. Cell Biol."},{"issue":"6","key":"10.1016\/j.cct.2020.106170_bb0100","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1002\/hep4.1057","article-title":"The new-generation pan-peroxisome proliferator-activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis","volume":"1","author":"Wettstein","year":"2017","journal-title":"Hepatology Commun."},{"key":"10.1016\/j.cct.2020.106170_bb0105","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jhep.2020.04.025","article-title":"Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages","volume":"73","author":"Lefere","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cct.2020.106170_bb0110","first-page":"S183","article-title":"PPAR agonist, in diabetic patients warrant further investigation","author":"Abitbol","year":"2016","journal-title":"J. Hepatol."},{"issue":"2","key":"10.1016\/j.cct.2020.106170_bb0115","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jhep.2016.04.005","article-title":"Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications","volume":"65","author":"Francque","year":"2016","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.cct.2020.106170_bb0120","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1002\/hep.20170","article-title":"Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice","volume":"39","author":"Ip","year":"2004","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cct.2020.106170_bb0125","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/jhep.2003.50307","article-title":"Central role of PPARalpha-dependent hepatic lipid turnover in dietary steatohepatitis in mice","volume":"38","author":"Ip","year":"2003","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cct.2020.106170_bb0130","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jhep.2015.02.019","article-title":"PPAR\u03b1 gene expression correlates with severity and histological treatment response in patients with non-alcoholic steatohepatitis","volume":"63","author":"Francque","year":"2015","journal-title":"J. Hepatol."},{"issue":"28","key":"10.1016\/j.cct.2020.106170_bb0135","doi-asserted-by":"crossref","first-page":"25448","DOI":"10.1074\/jbc.M301189200","article-title":"Specific gene expression of ATP-binding cassette transporters and nuclear hormone receptors in rat liver parenchymal, endothelial, and Kupffer cells","volume":"278","author":"Hoekstra","year":"2003","journal-title":"J. Biol. Chem."},{"issue":"45","key":"10.1016\/j.cct.2020.106170_bb0140","doi-asserted-by":"crossref","first-page":"12787","DOI":"10.3748\/wjg.v21.i45.12787","article-title":"Peroxisome proliferator-activated receptor-delta agonist ameliorated inflammasome activation in nonalcoholic fatty liver disease","volume":"21","author":"Lee","year":"2015","journal-title":"World J. Gastroenterol."},{"issue":"4","key":"10.1016\/j.cct.2020.106170_bb0145","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s11154-014-9298-4","article-title":"Pharmacological treatment and therapeutic perspectives of metabolic syndrome","volume":"15","author":"Lim","year":"2014","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"10.1016\/j.cct.2020.106170_bb0150","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1002\/hep.28985","article-title":"Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease","author":"Bril","year":"2017","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cct.2020.106170_bb0155","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.jhepr.2019.07.002","article-title":"From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options","volume":"1","author":"Gastaldelli","year":"2019","journal-title":"JHEP Reports"},{"issue":"6","key":"10.1016\/j.cct.2020.106170_bb0160","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/gt.2010.41","article-title":"PPARgamma is essential for protection against nonalcoholic steatohepatitis","volume":"17","author":"Wu","year":"2010","journal-title":"Gene Ther."},{"issue":"3","key":"10.1016\/j.cct.2020.106170_bb0165","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.dld.2007.10.002","article-title":"A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease","volume":"40","author":"Fernandez-Miranda","year":"2008","journal-title":"Dig. Liver Dis."},{"issue":"5","key":"10.1016\/j.cct.2020.106170_bb0170","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1053\/j.gastro.2016.01.038","article-title":"Elafibranor, an agonist of the peroxisome proliferator-activated receptor-\u03b1 and -\u03b4, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening","volume":"150","author":"Ratziu","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cct.2020.106170_bb0175","series-title":"GENFIT Announces Results from Interim Analysis of RESOLVE-IT Phase 3 Trial of Elafibranor in Adults with NASH and Fibrosis: Press Release","author":"GENFIT","year":"2020"},{"key":"10.1016\/j.cct.2020.106170_bb0180","series-title":"Cymabay Fourth Quarter Press Release","author":"Cymabay","year":"2020"},{"issue":"1","key":"10.1016\/j.cct.2020.106170_bb0185","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/j.1365-2036.2011.04912.x","article-title":"Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis","volume":"35","author":"Boettcher","year":"2012","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.cct.2020.106170_bb0190","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/jamainternmed.2016.9607","article-title":"Thiazolidinediones and advanced liver fibrosis in nonalcoholic steatohepatitis: a meta-analysis","volume":"177","author":"Musso","year":"2017","journal-title":"JAMA Intern. Med."},{"issue":"10","key":"10.1016\/j.cct.2020.106170_bb0195","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.2337\/dc16-0798","article-title":"Pioglitazone prevents diabetes in patients with insulin resistance and cerebrovascular disease","volume":"39","author":"Inzucchi","year":"2016","journal-title":"Diabetes Care"},{"issue":"17","key":"10.1016\/j.cct.2020.106170_bb0200","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph16173104","article-title":"Cardiovascular risk in non-alcoholic fatty liver disease: mechanisms and therapeutic implications","volume":"16","author":"Tana","year":"2019","journal-title":"Int. J. Environ. Res. Public Health"},{"issue":"5","key":"10.1016\/j.cct.2020.106170_bb0205","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1161\/ATVBAHA.108.179689","article-title":"Fibrates, glitazones, and peroxisome proliferator-activated receptors","volume":"30","author":"Lalloyer","year":"2010","journal-title":"Atherosclero. Thromb. Vascu. Biol."},{"key":"10.1016\/j.cct.2020.106170_bb0210","doi-asserted-by":"crossref","first-page":"2889","DOI":"10.1210\/jc.2011-1061","article-title":"MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin","volume":"9","author":"Bays","year":"2011","journal-title":"J. Clin. Endocrinol. Metabol."},{"issue":"5","key":"10.1016\/j.cct.2020.106170_bb0215","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.jhep.2011.12.008","article-title":"PPAR\u03b1 activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats","volume":"56","author":"Rodr\u00edguez-Vilarrupla","year":"2012","journal-title":"J. Hepatol."},{"issue":"7","key":"10.1016\/j.cct.2020.106170_bb0220","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.ajpath.2018.03.018","article-title":"Beneficial effects of the peroxisome proliferator-activated receptor \u03b1\/\u03b3 agonist Aleglitazar on progressive hepatic and splanchnic abnormalities in cirrhotic rats with portal hypertension","volume":"188","author":"Tsai","year":"2018","journal-title":"Am. J. Pathol."},{"issue":"9500","key":"10.1016\/j.cct.2020.106170_bb0225","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet."},{"issue":"9493","key":"10.1016\/j.cct.2020.106170_bb0230","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.cct.2020.106170_bb0235","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJMoa1506930","article-title":"Pioglitazone after ischemic stroke or transient ischemic attack","volume":"374","author":"Kernan","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.cct.2020.106170_bb0240","first-page":"914","article-title":"Pioglitazone and risk for bone fracture: safety data from a randomized clinical trial","volume":"102","author":"Viscoli","year":"2017","journal-title":"J. Clin. Endocrinol. Metabol."},{"key":"10.1016\/j.cct.2020.106170_bb0245","article-title":"Thiazolidinediones: the forgotten diabetes medications","volume":"151","author":"Lebovitz","year":"2019","journal-title":"Curr. Diabet. Reports"},{"issue":"1","key":"10.1016\/j.cct.2020.106170_bb0250","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12933-017-0617-4","article-title":"Pioglitazone and the secondary prevention of cardiovascular disease. A meta-analysis of randomized-controlled trials","volume":"16","author":"De Jong","year":"2017","journal-title":"Cardiovasc. Diabetol."},{"key":"10.1016\/j.cct.2020.106170_bb0255","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa1010949","article-title":"Pioglitazone for diabetes prevention in impaired glucose tolerance","volume":"12","author":"DeFronzo","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.cct.2020.106170_bb0260","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s13300-017-0273-4","article-title":"Pioglitazone and the risk of bladder Cancer: a meta-analysis","volume":"8","author":"Filipova","year":"2017","journal-title":"Diabet. Therapeut."},{"key":"10.1016\/j.cct.2020.106170_bb0265","article-title":"The pan-ppar agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease","author":"Aristu","year":"2019","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cct.2020.106170_bb0270","article-title":"Differential therapeutic effects of pan- and single PPAR agonists on steatosis, inflammation, macrophage composition and fibrosis in a murine model of non-alcoholic steatohepatitis","volume":"70","author":"Lefere","year":"2019","journal-title":"Oral Commun.-PS007"},{"key":"10.1016\/j.cct.2020.106170_bb0275","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/hep.27173","article-title":"Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease","volume":"60","author":"Bedossa","year":"2014","journal-title":"Hepatology."},{"issue":"8","key":"10.1016\/j.cct.2020.106170_bb0280","doi-asserted-by":"crossref","DOI":"10.3390\/cells8080845","article-title":"Current status in testing for nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH)","volume":"8","author":"Drescher","year":"2019","journal-title":"Cells."},{"issue":"2","key":"10.1016\/j.cct.2020.106170_bb0285","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jhep.2017.11.012","article-title":"Determinants of fibrosis progression and regression in NASH","volume":"68","author":"Schuppan","year":"2018","journal-title":"J. Hepatol."},{"issue":"10","key":"10.1016\/j.cct.2020.106170_bb0290","article-title":"Association of histologic disease activity with progression of nonalcoholic fatty liver disease","volume":"22","author":"Kleiner","year":"2019","journal-title":"JAWA Netw. Open"},{"issue":"6","key":"10.1016\/j.cct.2020.106170_bb0295","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"issue":"19","key":"10.1016\/j.cct.2020.106170_bb0300","first-page":"30721","article-title":"Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease","volume":"S0168-8278","author":"Nascimbeni","year":"2019","journal-title":"J. Hepatol."},{"issue":"10","key":"10.1016\/j.cct.2020.106170_bb0305","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1111\/apt.15503","article-title":"Standardising the interpretation of liver biopsies in non-alcoholic fatty liver disease clinical trials","volume":"50","author":"Pai","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.cct.2020.106170_bb0310","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/hep.29477","article-title":"A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis","volume":"67","author":"Friedman","year":"2018","journal-title":"Hepatology."},{"issue":"9972","key":"10.1016\/j.cct.2020.106170_bb0315","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"NASH clinical research network. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet."},{"issue":"10165","key":"10.1016\/j.cct.2020.106170_bb0320","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial","volume":"392","author":"Sanyal","year":"2019","journal-title":"Lancet."},{"key":"10.1016\/j.cct.2020.106170_bb0325","article-title":"NGM282 improves liver fibrosis and histology in 12 weeks in patients with nonalcoholic steatohepatitis","author":"Harrison","year":"2019","journal-title":"Hepatology"},{"issue":"22","key":"10.1016\/j.cct.2020.106170_bb0330","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1056\/NEJMoa060326","article-title":"A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis","volume":"355","author":"Belfort","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cct.2020.106170_bb0335","series-title":"The EPoS Staging System is a Reproducible 7-tier Fibrosis Score for NAFLD Adapted both to Glass Slides and Digitized Images (e-slides)","author":"Bedossa","year":"2018"},{"issue":"20","key":"10.1016\/j.cct.2020.106170_bb0340","article-title":"Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: results from randomized Ph III STELLAR Trials","volume":"S0168-8278","author":"Harrison","year":"2020","journal-title":"J. Hepatol."},{"key":"10.1016\/j.cct.2020.106170_bb0345","author":"GILEAD SCIENCES"},{"key":"10.1016\/j.cct.2020.106170_bb0350","article-title":"A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: study design of the TANDEM trial","volume":"88105889","author":"Pedrosa","year":"2020","journal-title":"Contemp. Clin. Trials."},{"issue":"5","key":"10.1016\/j.cct.2020.106170_bb0355","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1002\/hep.28610","article-title":"Successful antiviral treatment of chronic hepatitis C leads to a rapid decline of liver stiffness without an early effect on spleen stiffness","volume":"64","author":"Verlinden","year":"2016","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cct.2020.106170_bb0360","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/hep.28860","article-title":"Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood","volume":"65","author":"Decaris","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.cct.2020.106170_bb0365","author":"Ratziu"},{"key":"10.1016\/j.cct.2020.106170_bb0370","first-page":"47356","article-title":"Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR phase 2b study design","author":"Friedman","year":"2016","journal-title":"Contemp. Clin. Trials."},{"issue":"10213","key":"10.1016\/j.cct.2020.106170_bb0375","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"issue":"10215","key":"10.1016\/j.cct.2020.106170_bb0380","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.cct.2020.106170_bb0385","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.cgh.2018.06.011","article-title":"Rates of and factors associated with placebo response in trials of pharmacotherapies for nonalcoholic steatohepatitis: systematic review and meta-analysis","volume":"17","author":"Han","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714420302482?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714420302482?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:50:19Z","timestamp":1761555019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714420302482"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":77,"alternative-id":["S1551714420302482"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2020.106170","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: Design of the NATIVE study","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2020.106170","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"106170"}}